Clinical trialNCT06051695RecruitingPhase 1/PHASE2Interventional

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

SponsorA2 Biotherapeutics Inc.Enrollment474CRCCancerColon CancerColorectal AdenocarcinomaColorectal CancerLung Cancer+14 more conditions

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesothelioma (MESO), and other solid tumors that express mesothelin (MSLN) and have lost HLA-A\*02 expression. The main questions this study aims to answer are: Phase 1: What is the recommended dose that is safe for patients Phase 2: Does the recommended dose kill solid tumor cells and protect the patient's healthy cells Participants will be required to perform study procedures and assessments, and will also receive the following study treatments: Enrollment and Apheresis in BASECAMP-1 (NCT04981119) Preconditioning Lymphodepletion (PCLD) Regimen Tmod CAR T cells at the assigned dose

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

John Welch, MD, PhD
A2 Biotherapeutics
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

12 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Banner Health
Gilbert, Arizona, United States
Matthew Ulrickson, MD
Recruiting
Ucsd Moores Cancer Center
La Jolla, California, United States
Sandip Patel, MD
Recruiting
Ucla Medical Center
Los Angeles, California, United States
J. Randolph Hecht, MD
Recruiting
Stanford University
Stanford, California, United States
Oliver Dorigo, MD
Recruiting
Mayo Clinic
Jacksonville, Florida, United States
Yanyan Lou, MD
Recruiting
Moffitt Cancer Center
Tampa, Florida, United States
Monica Avila, MD
Recruiting
Mayo Clinic Rochester
Rochester, Minnesota, United States
Julian Molina, MD, PhD
Recruiting
Washington University
St Louis, Missouri, United States
Jeffery Ward, MD
Recruiting
Nyu Langone Medical Center
New York, New York, United States
Salman Punekar, MD
Recruiting
the Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
Jinesh Gheeya, MD, PhD
Recruiting
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Cathy Eng, M.D., FACP, FASCO
Recruiting
Fred Hutchinson Cancer Center
Seattle, Washington, United States
David Zhen, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

A2B543A2B694

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 3 Apr 2024
Primary completion: 30 Jun 2028
Completion: 30 Jun 2029
Last update posted: 12 Jun 2026
Registered enrollment: 474
Registry id: NCT06051695

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.